ReGen Biologics (OTC: RGBI) recently signed a distribution
agreement and initiated marketing for its products, including the
Menaflex(TM) collagen meniscus implant (formerly CMI(R)) in the United
Kingdom (U.K.).
The U.K. market introduction took place March 18 with two patient
surgeries at the Hospital of St. Cross in Rugby, West Midlands. The
surgeries were performed by Mr. Tim Spalding, FRCS Consultant
Orthopaedic Surgeon, assisted by Dr. Dirk Holsten of Koblenz, Germany.
ReGen products will be marketed and distributed in the UK through
Cardiff-based Hospital Innovations Ltd. Several training meetings are
planned for the Menaflex procedure, and interested surgeons may
contact Hospital Innovations directly regarding available dates and
locations in the U.K.
"We are pleased to make our Menaflex collagen meniscus implant
available to patients and surgeons in the United Kingdom, representing
a population of more than 60 million people," commented Marcel Kyburz,
General Manager of ReGen Biologics AG.
U.K. patients are encouraged to log onto www.menaflex.co.uk for
more information and a list of trained surgeons.
About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops,
manufactures and markets innovative tissue growth and repair products
for U.S. and global markets. ReGen´s patented collagen scaffold
technology includes applications in orthopedics, general surgery,
spine, cardiovascular and drug delivery. ReGen´s first approved
product using its collagen scaffold technology is the Menaflex(TM)
meniscus application, which is cleared for sale in Europe and other
countries and marketed through ReGen´s European subsidiary, ReGen
Biologics AG.
For more information visit www.regenbio.com.
About Hospital Innovations Ltd.
Hospital Innovations Limited is dedicated to providing clinicians
and patients with world class products and service. For more
information, visit www.hospitalinnovations.com.
